Table. Reconciliation of results of current and prior meta-analyses.

	Current	Huang 2019 PMID: 31296196	Rota 2019 PMID: 31046087	Wang 2018 PMID: 2997938	Snowsill (NHS)*, 2018 PMID: 26013989	Coureau 2016 PMID: 27211572	Usman Ali 2016 PMID: 2713053	Fu 2014 PMID 25307063	Manser (Cochrane), 2013 PMID 23794187	Humphrey (USPSTF) 2013 PMID: 23897166
Number of studies	9	9	7	4	4	5	4	4	1	4
Efficacy for lung cancer mortality reduction	0.84 (0.75, 0.93)	0.83 (0.76, 0.90)	0.80 (0.71, 0.90)	1.13 (0.78, 1.64) Exclude MILD 1.02 (0.66, 1.58)	0.94 (0.74, 1.19) Exclude MILD 0.85 (0.74, 0.98)	NA	Annual vs. usual 1.30 (0.81, 2.11) CXR Biennial vs. usual 1.45 (0.79, 2.69) LDCT vs. CXR (n = 1) 0.80 (0.70, 0.92)	0.84 (0.74, 0.96) Studies mislabeled	0.80 (0.70, 0.92)	Meta-analysis not performed due to heterogeneity
Heterogeneity	0%	1%	19%	87% Exclude MILD 85%	43% 6.9%	NA	40% NA NA	48%	NA (1 study)	High
Efficacy for overall mortality reduction	0.96 (0.91, 1.01)	0.95 (0.90, 1.00)		NA	1.00 (0.87, 1.16) Exclude MILD	NA	Annual LDCT vs. usual	1.04 (0.72, 1.51) Studies mislabeled	0.94 (0.88, 1.00)	Meta-analysis not performed

					0.95 (0.89, 1.00)		1.38 (0.86, 2.22) Biennial vs. usual 1.45 (0.79, 2.69) LDCT vs. CXR 0.94 (0.88, 0.998)				due to heterogeneity
Heterogeneity	0%	0%		NA	57% 0%	NA	80% NA NA	48%	NA (1 study)	High